BioCentury
ARTICLE | Company News

Acumen Pharmaceuticals, Merck deal

January 2, 2012 8:00 AM UTC

Acumen said Merck terminated an amended 2003 deal and returned rights to develop and commercialize anti-amyloid-derived diffusible ligand (ADDL) antibody therapeutics and diagnostics for Alzheimer's d...